Jasper Therapeutics Inc. recently provided a corporate presentation highlighting the efficacy, safety, and tolerability of their investigative drug, Briquilimab, in treating chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). The BEACON and SPOTLIGHT studies demonstrated rapid, deep, and durable responses, with significant improvements observed within four weeks post-dose. Additionally, an open-label extension study showed promising results with high complete response rates. Briquilimab was well tolerated, with most safety-related events resolving during repeat dosing. Upcoming milestones include further investigation into specific BEACON cohorts and additional data expected in late fourth quarter 2025. You can access the full presentation through the link below.